DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Fluo Labs, Inc. is a premarket clinical stage medical device company pursuing innovative technology to provide drug-free relief of nasal allergy (i.e. hay fever)...
TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and...
